Skip to main content
. 2016 Dec 21;5(4):46. doi: 10.3390/cells5040046

Figure 1.

Figure 1

Schematic illustration of the development process from patient-derived induced pluripotent stem (iPS) cells to a new medication. Outline (A) and addition of the processes necessary from both the scientific and regulatory perspectives. (B) Biomarker strategy is highlighted by the dotted box.